.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Accenture
US Department of Justice
Chinese Patent Office
Farmers Insurance
Citi
Harvard Business School
Cantor Fitzgerald
Merck
Moodys

Generated: July 22, 2017

DrugPatentWatch Database Preview

NIMBEX Drug Profile

« Back to Dashboard

What is the patent landscape for Nimbex, and when can generic versions of Nimbex launch?

Nimbex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIMBEX is cisatracurium besylate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

Summary for Tradename: NIMBEX

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list22
Clinical Trials: see list8
Patent Applications: see list169
Drug Prices:see details
DailyMed Link:NIMBEX at DailyMed

Pharmacology for Tradename: NIMBEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NIMBEX
cisatracurium besylate
INJECTABLE;INJECTION020551-001Dec 15, 1995APRXYesYes► Subscribe► Subscribe
Abbvie
NIMBEX PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION020551-003Dec 15, 1995APRXYesYes► Subscribe► Subscribe
Abbvie
NIMBEX PRESERVATIVE FREE
cisatracurium besylate
INJECTABLE;INJECTION020551-002Dec 15, 1995APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NIMBEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NIMBEX
cisatracurium besylate
INJECTABLE;INJECTION020551-001Dec 15, 19954,179,507► Subscribe
Abbvie
NIMBEX
cisatracurium besylate
INJECTABLE;INJECTION020551-001Dec 15, 19955,453,510► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NIMBEX

Drugname Dosage Strength RLD Submissiondate
cisatracurium besylate (preserve free)Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vialNimbex8/4/2009
cisatracurium besylate (multi-dose)     Injection2 mg/mL, 10 mL vialNimbex8/12/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Chinese Patent Office
Baxter
McKinsey
US Department of Justice
Merck
Colorcon
Farmers Insurance
Fuji
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot